Skip to main content
OpenTrials

Clinical trial condition

Neoplasm Metastasis

Explore clinical trials studying Neoplasm Metastasis. Study availability and eligibility vary by location and protocol.

2,438 public trials 498 recruiting studies
Refine in advanced search Browse all conditions

Neoplasm Metastasis trial results

Recruiting

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT03556228

Conditions
Adenocarcinoma, Adenoid Cystic Carcinoma, Adenoma, +65 more
Locations
  • Providence Medical Foundation (site 209) Santa Rosa, California, United States
  • Hartford Hospital (site 210) Hartford, Connecticut, United States
  • The George Washington University Cancer Center (site 212) Washington D.C., District of Columbia, United States
  • Holy Cross Hospital (site 213) Fort Lauderdale, Florida, United States
View all 15 locations
View Trial Details
Recruiting

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

NCT05859074

Conditions
Adenocarcinoma, Adenocarcinoma, Sebaceous, Adnexal Carcinoma, +58 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Recruiting

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

NCT07021898

Conditions
Metastatic Solid Tumors, Neoplasm Metastasis, Neoplasms, +3 more
Locations
  • Sarah Cannon Research Institute (SCRI) Oncology Partners Nashville, Tennessee, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • NEXT Oncology Irving, Texas, United States
  • NEXT Oncology San Antonio, Texas, United States
View Trial Details
Recruiting

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

NCT06333314

Conditions
Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +28 more
Locations
  • Institut de Cancérologie de l'Ouest Angers, France
  • Institut du Cancer Avignon-Provence Avignon, France
  • CHU Jean Minjoz Besançon, France
  • CHU Morvan Brest, France
View all 22 locations
View Trial Details
Recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

NCT06201234

Conditions
Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, +11 more
Locations
  • Vinzenz Von Paul Kliniken gGmbH - Marienhospital Stuttgart, Baden-Wurttemberg, Germany
  • University Hospital Tübingen Tübingen, Baden-Wurttemberg, Germany
  • Rems-Murr-Klinik-Winnenden Winnenden, Baden-Wurttemberg, Germany
  • GRN Klinik Weinheim Weinheim, Baden-Württembergs, Germany
View all 36 locations
View Trial Details
Recruiting

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

NCT07016230

Conditions
Metastatic/Locally Advanced High-grade MTC, Metastatic/Locally Advanced Poorly Differentiated NEC, Metastatic/Locally Advanced Small-Cell Lung Cancer, +5 more
Locations
  • Gustave Roussy Villejuif, France
View Trial Details

Related conditions